542 related articles for article (PubMed ID: 23684673)
1. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.
Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T;
J Am Coll Cardiol; 2013 Jul; 62(3):181-190. PubMed ID: 23684673
[TBL] [Abstract][Full Text] [Related]
2. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
4. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
Kimura T; Morimoto T; Natsuaki M; Shiomi H; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Takatsu Y; Nishikawa H; Yamamoto Y; Nakagawa Y; Hayashi Y; Iwabuchi M; Umeda H; Kawai K; Okada H; Kimura K; Simonton CA; Kozuma K;
Circulation; 2012 Sep; 126(10):1225-36. PubMed ID: 22824435
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
[TBL] [Abstract][Full Text] [Related]
6. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
7. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.
Vlachojannis GJ; Puricel S; Natsuaki M; Morimoto T; Smits PC; Kimura T
EuroIntervention; 2017 Mar; 12(16):1970-1977. PubMed ID: 27802927
[TBL] [Abstract][Full Text] [Related]
8. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).
Maeng M; Christiansen EH; Raungaard B; Kahlert J; Terkelsen CJ; Kristensen SD; Carstensen S; Aarøe J; Jensen SE; Villadsen AB; Lassen JF; Thim T; Eftekhari A; Veien KT; Hansen KN; Junker A; Bøtker HE; Jensen LO;
JACC Cardiovasc Interv; 2019 Apr; 12(7):624-633. PubMed ID: 30947936
[TBL] [Abstract][Full Text] [Related]
9. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial.
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Puricel S; Slagboom T; Goy JJ; den Heijer P; van der Ent M
EuroIntervention; 2015 Jul; 11(3):272-9. PubMed ID: 26196753
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Lee HJ; Park TK; Song YB; Choi YJ; Yu CW; Yang JH; Hahn JY; Choi SH; Choi RK; Choi JH; Park JS; Kim JS; Kim TH; Jang HJ; Lee SH; Shim WH; Roh YM; Gwon HC
Int J Cardiol; 2015 Mar; 183():190-7. PubMed ID: 25668147
[TBL] [Abstract][Full Text] [Related]
13. Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus: 5 years follow-up from the COMPARE II trial.
Paradies V; Vlachojannis GJ; Royaards KJ; Wassing J; van der Ent M; Smits PC
Int J Cardiol; 2019 Sep; 290():40-44. PubMed ID: 31101545
[TBL] [Abstract][Full Text] [Related]
14. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
[TBL] [Abstract][Full Text] [Related]
15. Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT).
Puricel S; Kallinikou Z; Espinola J; Arroyo D; Goy JJ; Stauffer JC; Baeriswyl G; Smits PC; Cook S; Togni M
Int J Cardiol; 2016 Jan; 202():525-31. PubMed ID: 26440470
[TBL] [Abstract][Full Text] [Related]
16. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial.
Natsuaki M; Watanabe H; Morimoto T; Kozuma K; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Hanaoka KI; Tanabe K; Morino Y; Ishikawa T; Katoh H; Nishikawa H; Tamura T; Ono K; Yamamoto K; Ishihara T; Abe M; Taniguchi R; Ikari Y; Okada K; Kimura T
EuroIntervention; 2023 Aug; 19(5):e402-e413. PubMed ID: 37395475
[TBL] [Abstract][Full Text] [Related]
18. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
[TBL] [Abstract][Full Text] [Related]
19. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
[TBL] [Abstract][Full Text] [Related]
20. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
